Citius Oncology Income Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022
Selling, General & Admin	17.34	15.65	7.88	2.86
Research & Development	5.04	4.93	4.24	6.86
Operating Expenses	22.38	20.57	12.12	9.71
Operating Income	-22.38	-20.57	-12.12	-9.71
Pretax Income	-22.38	-20.57	-12.12	-9.71
Income Tax Expense	0.7	0.58	0.58	1.15
Net Income	-23.08	-21.15	-12.7	-10.87
Net Income to Common	-23.08	-21.15	-12.7	-10.87
Shares Outstanding (Basic)	69	68	68	34
Shares Outstanding (Diluted)	69	68	68	34
Shares Change (YoY)	2.32%	0.82%	100.00%	-
EPS (Basic)	-0.33	-0.31	-0.19	-0.32
EPS (Diluted)	-0.33	-0.31	-0.19	-0.32
EBIT	-22.38	-20.57	-12.12	-9.71

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q